首页|血管介入治疗联合系统治疗在不可切除肝细胞癌中的研究进展

血管介入治疗联合系统治疗在不可切除肝细胞癌中的研究进展

Research progress of vascular interventional therapy combined with systemic therapy for unresectabl hepatocellular carcinoma

扫码查看
原发性肝癌是高发病率和高病死率的恶性肿瘤之一,在我国恶性肿瘤的发病率和病死率上也位居前列,严重威胁我国人民的生命和健康.大多数原发性肝癌患者发现时已经处于中晚期,丧失了手术机会,预后较差.近年来,随着肝动脉化疗栓塞及肝动脉灌注化疗等血管介入治疗技术的进步,以及新型酪氨酸激酶抑制剂、免疫检查点抑制剂的出现,尤其是多模式联合治疗的发展,使得不可切除肝细胞癌的治疗效果不断提升,也为序贯手术治疗提供了潜在的可能性.本文就血管介入治疗联合系统治疗在不可切除肝细胞癌中的研究进展进行综述,以期为不可切除肝细胞癌的临床治疗提供参考.
Primary liver cancer is a malignant tumor with high morbidity and mortality.It also ranks in the forefront in the incidence and mortality of malignant tumors in China,which seriously threatens the lives and health of Chinese people.Most patients have already been in the intermediate and late stage when they are diagnosed,thus the chance of surgery is lost,and the prognosis is poor.In recent years,with the advancement of vascular interventional therapy technologies such as hepatic arterial chemoembolization and hepatic arterial infusion chemotherapy,the emergence of new tyrosine kinase inhibitors,immune checkpoint inhibitors,and especially the development of multimodal combination therapy,the treatment effect of unre-sectable hepatocellular carcinoma has been continuously improved,and it also provides a potential possibility for sequential surgical treatment.This article reviews the research progress of vascular interventional therapy combined with systemic therapy in unresectable hepatocellular carcinoma,in order to provide a reference for the clinical treatment of unresectable hepatocellular carcinoma.

Carcinoma,hepatocellularVascular interventional therapySystemic therapyUnresectable

王小波、韦滔、吴飞翔

展开 >

广西医科大学附属肿瘤医院肝脏胰腺病区,南宁 530021

癌,肝细胞 血管介入治疗 系统治疗 不可切除

国家自然科学基金

82360537

2024

中华肝胆外科杂志
中华医学会

中华肝胆外科杂志

CSTPCD北大核心
影响因子:1.846
ISSN:1007-8118
年,卷(期):2024.30(2)
  • 48